<DOC>
	<DOCNO>NCT01752101</DOCNO>
	<brief_summary>The primary objective identify panel plasma and/or serum proteins differentiate absence presence lung malignancy sample obtain subject enrol IRB/EC approve study pulmonary nodule .</brief_summary>
	<brief_title>Identification Plasma Proteomic Signature Lung Cancer</brief_title>
	<detailed_description>Blood sample obtain patient undergoing procedure determine lung nodule benign cancerous . The data study use guide influence treatment patient enrol study . There change normal standard care patient receive .</detailed_description>
	<mesh_term>Precancerous Conditions</mesh_term>
	<criteria>age ≥ 40 smoking status , e.g . current , former , never comorbid condition , e.g . COPD Nodule size ≥ 4 mm ≤ 30 mm ( Stage 2B eligible ) , spiculation ground glass opacity Pathology : malignant adenocarcinoma , squamous , large cell Pathology : benign inflammatory ( e.g . granulomatous , infectious ) noninflammatory ( e.g . hamartoma ) Clinical stage , Primary tumor : ≤T2 ( e.g . 1A , 1B , 2A 2B ) Clinical stage , Regional lymph node : N0 N1 Clinical stage , Distant metastasis : M0 prior malignancy within 5 year lung nodule diagnosis No nodule size available No pathology data available Current diagnosis nonsmall cell lung cancer Clinical stage : Primary tumor ≥T3 ; Regional lymph node : ≥N2 ; 4 Distant metastasis : ≥M1</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Precancerous Conditions</keyword>
	<keyword>Carcinoma</keyword>
</DOC>